No abstract

No abstract

Background: Homozygous/compound heterozygous familial hypercholesterolemia (HoFH/cHeFH) is characterized by extremely elevated low-density lipoprotein-cholesterol (LDL-C) levels that have been reported to contribute to a long-term chronic systemic inflammation. The aims of this study are to describe the inflammatory profile of HoFH/cHeFH patients and explore the effect of PCSK9 inhibitor (PCSK9i) on a series of inflammatory biomarkers, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-HDL ratio (MHR), monocyte-lymphocyte ratio (MLR) and mean platelet volume-lymphocyte ratio (MPVLR). Methods: In this prospective cohort study, 21 definitive HoFH/cHeFH on high-intensity statins plus ezetimibe were placed on subcutaneous injections of PCSK9i 450mg every 4 weeks (Q4W). The biochemical parameters and inflammatory profile were analyzed at the day before PCSK9i therapy, 3 months and 6 months after PCSK9i therapy.Results: We found that HoFH/cHeFH on maximum tolerated statin dose plus ezetimibe displayed an elevated lipid and disturbed blood biomarker profile. After 3 months of add-on PCSK9i therapy, a significant reduction of LDL-C was observed. Meanwhile, percentage and count of neutrophils, monocyte counts, MPV, as well as two inflammatory biomarkers, NLR and MLR were reduced. However, at 6-month PCSK9i treatment, NLR and MLR returned to pre-PCSK9i treatment levels.Conclusions: PCSK9i induces a transient decrease in NLR and MLR in HoFH/cHeFH patients. Our results add evidence in evaluating the effects of PCSK9i on systemic inflammation.

No abstract

Background:Systemic immune-inflammation (SII) has been identified as an independent prognostic factor for many types of cancer. However, there is controversy regarding the prognostic value of SII in assessing non-small cell lung cancer (NSCLC) prognosis. Methods:In this study, we conducted a comprehensive search of the electronic databases of PubMed, Embase, and Cochrane Library up to March 21, 2023, to evaluate the prognostic value of SII in NSCLC. We calculated the hazard ratio (HR) and 95% confidence interval (CI) to assess the relationship between SII and overall survival (OS) or progression-free survival (PFS). Results: Our analysis included 32 studies involving 12,040 patients. The results showed that increased SII was significantly associated with poor OS (HR, 1.31; 95% CI, 1.21-1.41; p<0.001) and PFS (HR, 1.48; 95% CI 1.12-1.94; p<0.001) in NSCLC patients. Subgroup analysis further confirmed these findings. Sensitivity analysis and publication bias results indicated the stability of the results. Conclusions:Our study demonstrates that high SII is a significant predictor of poor OS and PFS in NSCLC patients. Therefore, SII may serve as a useful tool to evaluate the prognosis of NSCLC and guide the development of treatment strategies.